SHTG Daily Digest — Weiss Lab

A quiet week on top-tier journal lipid papers, but four solid next-tier publications span plozasiran's approval story, a machine-learning breakthrough for predicting which HTG patients will develop pancreatitis, lipidomic signatures of drug-refractory HTG, and pediatric monogenic HTG genetics; on the industry side, Ionis's platform scores a landmark hepatitis B win this week, keeping the ASO powerhouse in the spotlight while its Tryngolza sHTG approval decision looms by June 30.

A landmark Circulation imaging trial finds that olezarsen's dramatic triglyceride lowering does not translate into coronary plaque regression at 12 months—raising fundamental questions about TG-lowering as an atherosclerosis therapy just as the 2026 ACC/AHA dyslipidemia guideline reframes how we should think about hypertriglyceridemia, and with Ionis's PDUFA date for the SHTG indication just five weeks away.

A landmark ACC/AHA dyslipidemia guideline dropped this week alongside a pivotal Circulation imaging trial showing olezarsen's dramatic triglyceride reduction does not translate into coronary plaque regression — a sobering finding that reframes what APOC3 inhibition can and cannot achieve at 12 months; on the industry side, the two biggest near-term catalysts remain Ionis' June 30 PDUFA date for olezarsen in sHTG and Arrowhead's expected EU approval of REDEMPLO, both just outside this cycle's lookback window but essential context.

A landmark Circulation imaging trial shows olezarsen dramatically lowers triglycerides but does not shrink coronary plaque, while two new meta-analyses confirm robust TG and pancreatitis benefits across the ApoC-III inhibitor class, and on the industry side both Arrowhead and Ionis are sprinting toward a mid-2026 collision in the sHTG market.

A quiet top-tier journal week — no NEJM/Lancet/JAMA hits, but the next tier delivered three substantial APOC3-inhibitor meta-analyses (olezarsen, plozasiran, and the full ApoC-III class) all landing the same message: large triglyceride drops and a dramatic ~80% cut in acute pancreatitis risk, plus a new HNF4A–SPP2–LPL axis that could expand the SHTG target list; the industry side was equally subdued, dominated by Madrigal's $1B-biobucks pickup of an Arrowhead RNAi MASH asset and the run-up to Ionis' Tryngolza sHTG PDUFA at the end of June.

A thin top-tier journal week pushed Part A to the next-best tier, where ApoC-III inhibitors keep stacking up favorable meta-analytic evidence and a new HNF4A–SPP2–LPL axis hints at fresh small-molecule entry points; the industry side is also quiet — the dominant story over the past seven days remains the run-up to the late-June Tryngolza sHTG PDUFA, with no major company-specific lipid news from the allowed outlets.

No top-tier journal hits surfaced this week — showing the next-best tier — but the haul is unusually substantive: the first randomized evidence that an APOC3 siRNA (plozasiran) prevents recurrent pancreatitis in very severe hypertriglyceridemia, a major Hegele review repositioning ANGPTL3 as a remnant-cholesterol target, and new human data linking ANGPTL3/4/8 complexes to heart failure outcomes.

A genuinely consequential week — the 2026 ACC/AHA dyslipidemia guideline lands in Circulation and explicitly incorporates hypertriglyceridemia and Lp(a) management, while NEJM publishes a three-letter correspondence exchange that pressure-tests the CORE-TIMI 72 olezarsen pancreatitis data.

This week's top-tier literature is anchored by the new 2026 ACC/AHA Dyslipidemia Guideline — the most comprehensive update to U.S. lipid management in eight years — alongside a cluster of NEJM correspondence debating the landmark olezarsen APOC3-targeting RCT and its implications for pancreatitis prevention in severe hypertriglyceridemia.

A thin but consequential week — the new 2026 ACC/AHA multisociety dyslipidemia guideline lands in Circulation with hypertriglyceridemia and Lp(a) carved out as first-class targets, and three NEJM correspondence pieces continue the post-publication debate over olezarsen's pancreatitis benefit in severe hypertriglyceridemia.